secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspira Women's Health Inc. (AWHL)
CIK:        0000926617
Form:       8-K/A
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0000926617-23-000072
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aspira Women's Health Q2 revenue $2.5M, up 23% YoY; cash burn down 46%
----------------------------------------------------------------------

- Q2 2023 revenue $2.5M (+23% YoY); OvaSuite volume 6,289 (+16%); gross margin 62% vs 47% in Q2 2022.
- Cash used in operations $3.4M, down 46% from $6.3M in Q2 2022; total cash $4.5M at June 30.
- Lowered H2 2023 operating cash guidance to $6–8M; received $1M debt forgiveness from Connecticut DECD.
- Raised $4.3M net in July 2023 registered direct offering; total outstanding debt ~$1.6M.
- Appointed Torsten Hombeck as CFO; COO/CSO Ryan Phan to depart Sept 15; new director Winfred Parnell appointed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/926617/000092661723000072/0000926617-23-000072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/926617/000092661723000072/awh-20230814x8ka.htm
  HTML page:      https://secwatch.observer/filing/0000926617-23-000072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer